Myasthenia Gravis Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL MYASTHENIA GRAVIS INDUSTRY

2.1 Summary about Myasthenia Gravis Industry

2.2 Myasthenia Gravis Market Trends

2.2.1 Myasthenia Gravis Production & Consumption Trends

2.2.2 Myasthenia Gravis Demand Structure Trends

2.3 Myasthenia Gravis Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Drug Treatment 

4.2.2 Rapid Immunotherapies

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospitals 

4.3.2 Clinics 

4.3.3 Others

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Drug Treatment 

5.2.2 Rapid Immunotherapies

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospitals 

5.3.2 Clinics 

5.3.3 Others

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Drug Treatment 

6.2.2 Rapid Immunotherapies

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospitals 

6.3.2 Clinics 

6.3.3 Others

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Drug Treatment 

7.2.2 Rapid Immunotherapies

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospitals 

7.3.2 Clinics 

7.3.3 Others

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Drug Treatment 

8.2.2 Rapid Immunotherapies

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospitals 

8.3.2 Clinics 

8.3.3 Others

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Drug Treatment 

9.2.2 Rapid Immunotherapies

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospitals 

9.3.2 Clinics 

9.3.3 Others

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Shire 

10.1.2 F. Hoffmann-La Roche 

10.1.3 CSL Behring 

10.1.4 Grifols 

10.1.5 Alexion Pharmaceutical 

10.1.6 Avadel Pharmaceuticals 

10.1.7 Baxter International 

10.1.8 Novartis 

10.1.9 Valeant Pharmaceuticals International 

10.1.10 Takeda Pharmaceutical Company

10.2 Myasthenia Gravis Sales Date of Major Players (2017-2020e)

10.2.1 Shire 

10.2.2 F. Hoffmann-La Roche 

10.2.3 CSL Behring 

10.2.4 Grifols 

10.2.5 Alexion Pharmaceutical 

10.2.6 Avadel Pharmaceuticals 

10.2.7 Baxter International 

10.2.8 Novartis 

10.2.9 Valeant Pharmaceuticals International 

10.2.10 Takeda Pharmaceutical Company

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

Table Myasthenia Gravis Product Type Overview

Table Myasthenia Gravis Product Type Market Share List

Table Myasthenia Gravis Product Type of Major Players

Table Brief Introduction of Shire 

Table Brief Introduction of F. Hoffmann-La Roche 

Table Brief Introduction of CSL Behring 

Table Brief Introduction of Grifols 

Table Brief Introduction of Alexion Pharmaceutical 

Table Brief Introduction of Avadel Pharmaceuticals 

Table Brief Introduction of Baxter International 

Table Brief Introduction of Novartis 

Table Brief Introduction of Valeant Pharmaceuticals International 

Table Brief Introduction of Takeda Pharmaceutical Company

Table Products & Services of Shire 

Table Products & Services of F. Hoffmann-La Roche 

Table Products & Services of CSL Behring 

Table Products & Services of Grifols 

Table Products & Services of Alexion Pharmaceutical 

Table Products & Services of Avadel Pharmaceuticals 

Table Products & Services of Baxter International 

Table Products & Services of Novartis 

Table Products & Services of Valeant Pharmaceuticals International 

Table Products & Services of Takeda Pharmaceutical Company

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Myasthenia Gravis Market Forecast (Million USD) by Region 2021f-2026f

Table Global Myasthenia Gravis Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Myasthenia Gravis Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Myasthenia Gravis Market Forecast (Million USD) Share by Demand 2021f-2026f